Comparing ProPhase Labs (NASDAQ:PRPH) and NLS Pharmaceutics (NASDAQ:NCEL)

ProPhase Labs (NASDAQ:PRPH) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Profitability

This table compares ProPhase Labs and NLS Pharmaceutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
NLS Pharmaceutics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings for ProPhase Labs and NLS Pharmaceutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1	0	0	0	1.00
NLS Pharmaceutics	1	0	0	0	1.00

Institutional and Insider Ownership

9.4% of ProPhase Labs shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares ProPhase Labs and NLS Pharmaceutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06 million	0.18	-$53.36 million	($3.90)	-0.04
NLS Pharmaceutics	N/A	N/A	-$1.98 million	N/A	N/A

NLS Pharmaceutics has lower revenue, but higher earnings than ProPhase Labs.

Risk & Volatility

ProPhase Labs has a beta of -0.56, meaning that its stock price is 156% less volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500.

Summary

NLS Pharmaceutics beats ProPhase Labs on 6 of the 8 factors compared between the two stocks.

About ProPhase Labs

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.